DYNAVAX TECHNOLOGIES CORP (DVAX) Fundamental Analysis & Valuation

NASDAQ:DVAX • US2681582019

Current stock price

15.5 USD
0 (0%)
At close:
15.5 USD
0 (0%)
After Hours:

This DVAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. DVAX Profitability Analysis

1.1 Basic Checks

  • In the past year DVAX was profitable.
  • In the past year DVAX had a positive cash flow from operations.
  • In multiple years DVAX reported negative net income over the last 5 years.
  • DVAX had a positive operating cash flow in 4 of the past 5 years.
DVAX Yearly Net Income VS EBIT VS OCF VS FCFDVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

1.2 Ratios

  • DVAX's Return On Assets of -4.59% is amongst the best of the industry. DVAX outperforms 86.40% of its industry peers.
  • DVAX has a Return On Equity of -8.13%. This is amongst the best in the industry. DVAX outperforms 88.70% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.05%, DVAX belongs to the top of the industry, outperforming 89.08% of the companies in the same industry.
Industry RankSector Rank
ROA -4.59%
ROE -8.13%
ROIC 1.05%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
DVAX Yearly ROA, ROE, ROICDVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • In the last couple of years the Profit Margin of DVAX has declined.
  • The Operating Margin of DVAX (3.16%) is better than 89.46% of its industry peers.
  • With an excellent Gross Margin value of 83.17%, DVAX belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of DVAX has grown nicely.
Industry RankSector Rank
OM 3.16%
PM (TTM) N/A
GM 83.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
DVAX Yearly Profit, Operating, Gross MarginsDVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DVAX Health Analysis

2.1 Basic Checks

  • DVAX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, DVAX has less shares outstanding
  • The number of shares outstanding for DVAX has been increased compared to 5 years ago.
  • Compared to 1 year ago, DVAX has a worse debt to assets ratio.
DVAX Yearly Shares OutstandingDVAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DVAX Yearly Total Debt VS Total AssetsDVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.44 indicates that DVAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • DVAX has a Altman-Z score of 2.44. This is in the better half of the industry: DVAX outperforms 67.24% of its industry peers.
  • DVAX has a debt to FCF ratio of 3.24. This is a good value and a sign of high solvency as DVAX would need 3.24 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.24, DVAX belongs to the best of the industry, outperforming 92.34% of the companies in the same industry.
  • DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • DVAX has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: DVAX underperforms 69.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 3.24
Altman-Z 2.44
ROIC/WACC0.13
WACC8.24%
DVAX Yearly LT Debt VS Equity VS FCFDVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • DVAX has a Current Ratio of 7.62. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
  • DVAX's Current ratio of 7.62 is fine compared to the rest of the industry. DVAX outperforms 72.99% of its industry peers.
  • A Quick Ratio of 6.94 indicates that DVAX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.94, DVAX is doing good in the industry, outperforming 69.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.62
Quick Ratio 6.94
DVAX Yearly Current Assets VS Current LiabilitesDVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. DVAX Growth Analysis

3.1 Past

  • DVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 211.54%, which is quite impressive.
  • DVAX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.10% yearly.
  • DVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.73%.
  • Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%

3.2 Future

  • Based on estimates for the next years, DVAX will show a very strong growth in Earnings Per Share. The EPS will grow by 63.12% on average per year.
  • DVAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.42% yearly.
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DVAX Yearly Revenue VS EstimatesDVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DVAX Yearly EPS VS EstimatesDVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

5

4. DVAX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 37.80, which means the current valuation is very expensive for DVAX.
  • Based on the Price/Earnings ratio, DVAX is valued cheaper than 91.95% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. DVAX is valued slightly more expensive when compared to this.
  • With a Price/Forward Earnings ratio of 28.84, DVAX can be considered very expensive at the moment.
  • 91.76% of the companies in the same industry are more expensive than DVAX, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 21.36. DVAX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 37.8
Fwd PE 28.84
DVAX Price Earnings VS Forward Price EarningsDVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • DVAX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DVAX is cheaper than 90.61% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DVAX is valued cheaper than 95.02% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.88
EV/EBITDA 66.27
DVAX Per share dataDVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • DVAX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as DVAX's earnings are expected to grow with 63.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.81%
EPS Next 3Y63.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DVAX Dividend Analysis

5.1 Amount

  • No dividends for DVAX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DVAX Fundamentals: All Metrics, Ratios and Statistics

DYNAVAX TECHNOLOGIES CORP

NASDAQ:DVAX (2/9/2026, 8:00:01 PM)

After market: 15.5 0 (0%)

15.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)11-05
Earnings (Next)02-18
Inst Owners98.72%
Inst Owner Change-4.16%
Ins Owners0.71%
Ins Owner Change-2122.58%
Market Cap1.76B
Revenue(TTM)330.51M
Net Income(TTM)-43.40M
Analysts80
Price Target20.91 (34.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.4%
Min EPS beat(2)30.1%
Max EPS beat(2)64.71%
EPS beat(4)3
Avg EPS beat(4)6.21%
Min EPS beat(4)-86.66%
Max EPS beat(4)64.71%
EPS beat(8)6
Avg EPS beat(8)-6.9%
EPS beat(12)9
Avg EPS beat(12)66.09%
EPS beat(16)11
Avg EPS beat(16)67.73%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-4.19%
Max Revenue beat(4)7.97%
Revenue beat(8)2
Avg Revenue beat(8)-2.29%
Revenue beat(12)6
Avg Revenue beat(12)3.06%
Revenue beat(16)8
Avg Revenue beat(16)4.4%
PT rev (1m)-1.2%
PT rev (3m)-14.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45%
EPS NY rev (1m)0%
EPS NY rev (3m)12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 37.8
Fwd PE 28.84
P/S 5.33
P/FCF 21.88
P/OCF 19.44
P/B 3.3
P/tB 3.31
EV/EBITDA 66.27
EPS(TTM)0.41
EY2.65%
EPS(NY)0.54
Fwd EY3.47%
FCF(TTM)0.71
FCFY4.57%
OCF(TTM)0.8
OCFY5.14%
SpS2.91
BVpS4.7
TBVpS4.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.58367 (-57.52%)
Profitability
Industry RankSector Rank
ROA -4.59%
ROE -8.13%
ROCE 1.24%
ROIC 1.05%
ROICexc 3.98%
ROICexgc 4.02%
OM 3.16%
PM (TTM) N/A
GM 83.17%
FCFM 24.37%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 3.24
Debt/EBITDA 20.41
Cap/Depr 429.21%
Cap/Sales 3.05%
Interest Coverage 2.16
Cash Conversion 708.62%
Profit Quality N/A
Current Ratio 7.62
Quick Ratio 6.94
Altman-Z 2.44
F-Score5
WACC8.24%
ROIC/WACC0.13
Cap/Depr(3y)139.55%
Cap/Depr(5y)160.56%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year458.87%
EBIT Next 3Y103.78%
EBIT Next 5YN/A
FCF growth 1Y-31.63%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3Y-41.69%
OCF growth 5YN/A

DYNAVAX TECHNOLOGIES CORP / DVAX Fundamental Analysis FAQ

What is the fundamental rating for DVAX stock?

ChartMill assigns a fundamental rating of 6 / 10 to DVAX.


Can you provide the valuation status for DYNAVAX TECHNOLOGIES CORP?

ChartMill assigns a valuation rating of 6 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.


What is the profitability of DVAX stock?

DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 6 / 10.


How financially healthy is DYNAVAX TECHNOLOGIES CORP?

The financial health rating of DYNAVAX TECHNOLOGIES CORP (DVAX) is 6 / 10.


What is the earnings growth outlook for DYNAVAX TECHNOLOGIES CORP?

The Earnings per Share (EPS) of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to decline by -318.17% in the next year.